ISEE — IVERIC bio Share News
0.000.00%
Last trade - 00:00HealthcareAdventurousLarge Cap
Iveric Bio Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: Iveric Bio Announces Pricing Of Upsized Public Offering Of Common Stock
Brief: Iveric Bio Does Not Expect To Initiate Phase 1/2 Clinical Trial For IC-200 In 2021
Brief: Iveric Bio Announces Proposed Offering Of Common Stock
Aphellis falls after mixed results from eye drug trials; rival Iveric soars
U.S. RESEARCH ROUNDUP-Aspen Aerogels, Editas Medicine, Humanigen
Iveric Bio rises as Wainwright starts coverage with 'outperform' rating
Iveric Bio Inc reports results for the quarter ended in June - Earnings Summary
Brief: Iveric Bio Reports Second Quarter 2021 Operational Highlights And Financial Results
Iveric Bio Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Iveric Bio Completes Patient Enrollment Of GATHER2 Clinical Trial Of Zimura Before Schedule
Brief: Iveric Bio Appoints Christopher Simms As Chief Commercial Officer
U.S. STOCKS ON THE MOVE-PepsiCo, JPMorgan, Orbsat, Two Harbors Investment
Iveric Bio drops on $100 mln stock deal
Brief: Iveric Bio Inc Announces Pricing Of $100 Million Public Offering Of Common Stock
Brief: Iveric Bio - Expects Top-Line Data From Gather2 To Become Available During H2 Of 2022
Brief: Iveric Bio Inc Announces Proposed Offering Of Common Stock
U.S. STOCKS ON THE MOVE-Iveric Bio, DiDi Global, Advaxis Inc
Iveric Bio rises as FDA agrees to eye disorder study design